Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Current Deferred Revenue for 8 consecutive years, with $18.8 million as the latest value for Q1 2026.

  • Quarterly Current Deferred Revenue fell 38.69% to $18.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Feb 2026, down 38.69% year-over-year, with the annual reading at $17.6 million for FY2025, 54.18% down from the prior year.
  • Current Deferred Revenue for Q1 2026 was $18.8 million at Nurix Therapeutics, up from $17.6 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $48.1 million in Q4 2023, with the low at $17.6 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $36.5 million, with a median of $38.3 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue soared 49.82% in 2024, then crashed 54.18% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $37.6 million in 2022, then grew by 27.81% to $48.1 million in 2023, then dropped by 20.24% to $38.4 million in 2024, then plummeted by 54.18% to $17.6 million in 2025, then rose by 6.68% to $18.8 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $18.8 million, $17.6 million, and $26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.